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Selective  targeting  of  tumor  cells  by nanoparticle-based  drug  delivery  systems  is  highly desirable  because
it maximizes  the drug  concentration  at the  desired  target  while  simultaneously  protecting  the  surround-
ing healthy  tissues.  Here,  we show  a  design  for  smart  nanocarriers  based  on a biomimetic  approach
that  utilizes  the  building  principle  of  virus  envelope  structures.  Emulsomes  and CurcuEmulsomes  com-
prising  a tripalmitin  solid  core  surrounded  by  phospholipid  layers  are  modiﬁed  by S-layer  proteins  that
self-assemble  into  a  two-dimensional  array  to form  a surface  layer.  One  signiﬁcant  advantage  of  thismulsomes
urcumin
-layer (fusion) proteins
mmunoglobulin G (IgG) Targeting
ctive drug delivery
nanoformulation  is  that  it increases  the  solubility  of  the  lipophilic  anti-cancer  agent  curcumin  in  the  Cur-
cuEmulsomes  by a factor  of 2700.  In order  to make  the emulsomes  speciﬁc  for  IgG, the S-layer  protein  is
fused  with two  protein  G domains.  This  S-layer  fusion  protein  preserves  its recrystallization  characteris-
tics,  forming  an  ordered  surface  layer  (square  lattice  with  13  nm  unit-by-unit  distance).  The  GG  domains
are  presented  in  a predicted  orientation  and  exhibit  a selective  binding  afﬁnity  for  IgG.
ublis© 2015  The  Authors.  P
. Introduction
Many studies provide evidence that the use of nanoparticle-
ediated targeted drug delivery systems (DDS) minimizes drug
egradation and inactivation upon administration while increasing
rug bioavailability and the fraction of drug delivered in the patho-
ogical area [1–3]. Active targeting implies tailor-made surface
odiﬁcations of nanoparticles with ligands that bind to speciﬁc
eceptors expressed on target cells.
In nature, viruses are extremely effective at targeting cells and
elivering genomes into their host. One remarkable property of
iruses is a regular and well-deﬁned proteinaceous structure called
 capsid [4]. This feature can also be observed on many bacteria and
ost archaea, which carry a crystalline cell surface (S-) layer as the
∗ Corresponding author at: Department of Biomedical Engineering, School of Engi-
eering and Natural Sciences, Istanbul Medipol University, Ekinciler Cad. No. 19
avacık Kavs¸ ag˘ı, Beykoz 34810, Istanbul, Turkey. Tel.: +90 216 681 5154;
ax: +90 212 531 7555.
E-mail address: m.h.ucisik@gmail.com (M.H. Ucisik).
ttp://dx.doi.org/10.1016/j.colsurfb.2015.01.055
927-7765/© 2015 The Authors. Published by Elsevier B.V. This is an open access article uhed  by Elsevier  B.V. This  is  an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).
outermost envelope structure [5,6]. Composed of a single protein
or glycoprotein species [7], S-layer lattices can be employed to act
as an anti-fouling layer [8] and to decrease the cytotoxicity of blank
nanocarriers such as polymeric capsules [9] and emulsomes [10],
thereby improving the bioavailability of enclosed drugs.
Members of the immunoglobulin superfamily are among the
most common selected targets for directing drugs to cells of inter-
est, particularly inﬂammatory and cancer cells [11]. Binding to
immunoglobulin G (IgG) is known to be important for the opsoniza-
tion process, which can further activate the classical component
pathway presenting particulates or colloidal carriers to phagocytes
[12]. It has also been reported that IgG secreted by human cancers
promotes growth and survival of tumor cells [13]. Hence, IgG may
serve as a potential therapeutic target in cancer therapy.
Lipid-based nanocarrier systems are attractive because of
their biocompatibility, biodegradability and their ability to entrap
hydrophilic and hydrophobic drugs [14]. Emulsomes are a form
of lipid-based nanocarrier with an internal solid fat core sur-
rounded by a phospholipid multilayer [15–17]. They offer both high
loading capacity for hydrophobic substances [18] and controlled
drug release [16,19]. Moreover, the phospholipid surface can be
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
aces B
a
l
t
m
c
i
a
c
s
t
n
t
i
t
c
t
G
p
s
e
s
f
2
2
1
t
I
p
(
(
G
A
c
i
(
f
2
T
(
s
b
(
w
p
r
a
o
a
2
E
B
t
c
oM.H. Ucisik et al. / Colloids and Surf
dapted to various surface modiﬁcations already established for
iposomes to control the targeting or enhance circulation residence
ime [20–22]. The surface of emulsomes can also be coated and
odiﬁed with S-layer proteins to bestow the nanocarriers with the
haracteristic features of the S-layer lattice [10].
Mimicking the building principle of virus envelopes, this study
ntroduces an emulsome-based targeted DDS for the anti-cancer
gent curcumin. The medical use of this natural polyphenol is
urrently limited due to its extremely low water solubility. The
olubility of curcumin, however, can be enhanced via encapsula-
ion in emulsomes, which produces nanocarriers that have been
amed CurcuEmulsomes [19]. CurcuEmulsomes not only facilitate
he delivery of curcumin to the human liver carcinoma cell HepG2
n vitro, but also prolong the biological effect by triggering con-
rolled drug release inside the cell [19].
The present study investigates how S-layer fusion technology
an be applied to emulsomes and CurcuEmulsomes to promote
argeted delivery to IgG. For this purpose, the fusion protein rSbpA-
G was designed with two protein G domains fused to the S-layer
rotein SbpA from Lysinibacillus sphaericus CCM 2177. The present
tudy involves the genetic design and expression of rSbpA-GG and
xplores its self-assembly and IgG-binding characteristics on emul-
omes. This study will contribute to the utilization of emulsomes
or delivery of lipophilic therapeutics in nanomedicine.
. Materials and methods
.1. Materials
Curcumin, glyceryl tripalmitate (tripalmitin, purity ≥99%),
,2-dipalmitoyl-rac-glycero-3-phosphocholine (DPPC, ∼99%), glu-
araldehyde solution (50%), human IgG-Reagent Grade, anti-human
gG (-chain speciﬁc)-gold antibody, Sudan III and FITC were
urchased from Sigma–Aldrich GmbH, Germany. Hexadecylamine
HDA, ≥99%), uranyl acetate dehydrate (≥98%) and chloroform
≥99.8%) were obtained from Fluka Chemika, Switzerland and
ermany, respectively. Cholesterol (>%98) was purchased from
vanti Polar Lipids, USA. Dimethyl sulfoxide (DMSO) was  pur-
hased from Riedel-de Haën (Sigma–Aldrich, Germany) and
sopropyl--d-thiogalactoside (IPTG) was purchased from Gerbu
Gaiberg, Germany). All chemicals were used as received without
urther puriﬁcation.
.2. Cloning of the recombinant plasmid pET28a/rsbpA31-1068/gg
All PCRs were performed as described in Jarosch et al. [23].
he two GG domains were ampliﬁed by PCR from plasmid SPG1
Genart, Regensburg, Germany) containing two  copies of the gene
equence encoding the G domain with a glycine/glycine linker in
etween as well as the restriction sites BamHI (upstream) and XhoI
downstream). The DNA sequence encoding the two  G domains
as ligated into the two corresponding restriction sites of plasmid
ET28a containing the gene rsbpA31-1068 encoding S-layer protein
SbpA31-1068. Digestion of DNA with restriction endonucleases, sep-
ration of DNA fragments by agarose gel electrophoresis, ligation
f DNA fragments and transformation procedures were performed
s previously described [24].
.3. Heterologous expression of the fusion protein rSbpA-GG
The construct pET28a–rsbpA31-1068/gg was  cloned in
scherichia coli TG1 and heterologously expressed in E. coli
L21 (DE3) Star as previously described [24]. The plasmid stability
est was performed as described previously [23]. Expression of the
himeric gene encoding rSbpA-GG was induced by the addition
f IPTG to a ﬁnal concentration of 1 mM at an attenuance (D600): Biointerfaces 128 (2015) 132–139 133
of 0.6–0.8. Expression was  carried out at 37 ◦C for 4 h. Samples
(2 mL)  were taken before and at 1, 2 and 4 h after induction of gene
expression and run on SDS-PAGE. SDS-PAGE was performed as
described previously [23].
2.4. Isolation of S-layer fusion protein SbpA-GG
After 4 h of expression, isolation of rSbpA-GG from E. coli
BL21(DE3) Star cells was  performed using Bacterial Protein Extrac-
tion Reagent (B-PER) following a modiﬁed protocol. The B-PER
was purchased from Pierce (Rockford, IL, USA). Biomass pellets
(2 g) were initially resuspended in 20 mL  of B-PER. After incuba-
tion for 10 min  at room temperature the solution was  centrifuged
(20,000 × g, 15 min, 4 ◦C). Subsequently, the pellet was resuspended
in 20 mL of B-PER containing and 4 mg  of lysozyme (Sigma, Munich,
Germany) and incubated for 5 min at room temperature. 20 L of
1 mg  mL−1 DNAseI solution (Roche, Basel, Switzerland) and 1 mL
of a 0.1 M MgSO4·7H2O solution were added and the suspen-
sion was  incubated for 30 min  at room temperature. Subsequently,
100 mL  of B-PER (diluted 1:10 in distilled water) was added and
the solution was  centrifuged (20,000 × g, 20 min, 4 ◦C). After two
washing steps with 30 mL  of diluted B-PER and one washing step
with 30 mL  of 50 mM Tris/HCl buffer (pH 7.2) with 1 mM dithio-
threitol (DTT), the suspension was  centrifuged (20,000 × g, 20 min,
4 ◦C) and the obtained pellet was  resuspended in 3.5 mL  of 4 M
guanidine hydrochloride (GHCl) dissolved in 50 mM  Tris/HCl buffer
(pH 7.2) and stirred for 30 min  at room temperature. The suspen-
sion was diluted to a ﬁnal GHCl concentration of 2 M.  To remove
membrane fragments, the suspension was centrifuged (36,000 × g,
30 min, 4 ◦C), the supernatant was ﬁltered through a ﬁlter mem-
brane with pore size of 0.45 m (Minisart RC 25) and the ﬁltrate
was subjected to GPC (gel-permeation chromatography) using
a Superdex 200 column (Amersham Biosciences, Little Chalfont,
Bucks, UK) equilibrated in degassed 50 mM Tris/HCl buffer (pH
7.2) with 150 mM NaCl, for separation. Fractions containing the
fusion protein rSbpA-GG were pooled, dialysed against Milli-Q
water for 18 h at 4 ◦C, lyophilized and stored at −20 ◦C. For detection
of the GG portion, the fusion protein rSbpA-GG was subjected to
SDS-PAGE.
2.5. Preparation of rSbpA-GG ELISA plates
Lyophilized rSbpA-GG was  dissolved in 5 M GHCl/Tris buffer (pH
7.2) and dialysed against 3 L Milli-Q water at RT for 3 h (BioMol:
Dialysis membrane type 8; cut-off 12–16 kDa). Water was changed
three times: after 30 min, 60 min  and then after 90 min. Subse-
quently the solution was  centrifuged at 14,000 rpm for 5 min  and
the protein concentration of the supernatant was determined using
UV 280 nm measurements and adjusted to 1 mg  mL−1. The solu-
tion was  diluted with crystallization buffer (0.5 mM Tris, 10 mM
CaCl2, pH 9.5) to a ﬁnal concentration of 100 g mL−1 protein. From
this solution 110 L was  transferred to each well of an ELISA plate
(Microlon 200; GREINER, medium capacity). Crystallization was
performed at 4 ◦C overnight. Unbound S-layer protein was  washed
away with crystallization buffer. Subsequently, the S-layer pro-
tein was stabilized and blocked by an incubation step with 250 L
StabilGuard (SurModics; 1:1 PBS/Triton X 100) per well at RT for
4 h. The liquid was  removed and the plates were dried at 37 ◦C
overnight.
2.6. Estimation of IgG binding afﬁnity of rSbpA-GG by ELISAThe rSbpA-GG plates were incubated with peroxidase-labeled
anti-human IgG developed in goat (=anti-human IgG POX, Sigma
A0293 Fab speciﬁc developed in goat; 1:5000 in blocking buffer) at
RT for 30 min. After 3 washing steps with 250 L PBS/Triton X-100,
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ound IgG POX was detected using 3,3′,5,5′-tetramethylbenzidine
ihydrochloride (TMB; Sigma, T-3405) as substrate; 200 L TMB
olution was added per well and the color development was
topped by addition of 50 L 2 M H2SO4. Subsequently, the yellow
olor of the samples was read at 450 nm (reference ﬁlter 630 nm)
ith an ELISA Reader. As a control, an identical assay was performed
ith rSbpA and the S-layer fusion protein rSbpA-ZZ comprising
rotein A [24].
.7. Preparation of emulsomes and CurcuEmulsomes
Emulsomes were prepared as described previously [10]. Cur-
uEmulsomes with two different curcumin concentrations were
repared as described in Ucisik et al. [19]. Accordingly, one prepara-
ion has prepared as before with the curcumin–tripalmitin weight
atio of 2:5 [19], whereas the other with a weight ratio of 1:10.
he DPPC, cholesterol and HDA molar ratio was as before 10:5:4.
he suspension was ﬁltered at 66 ◦C through polycarbonate ﬁlters
three passes through 800 nm pore ﬁlters, followed by 2 passes
hrough 400 nm pore ﬁlters; ﬁlters from Nucleopore Track Etch
embrane, Whatman, UK). The ﬁltrate was placed immediately on
ce for a 10 min  period, followed by centrifugation at 13,200 rpm
16,100 × g) for 10 min  to spin down unincorporated curcumin. The
urcuEmulsome suspension, i.e., the supernatant, was stored at
◦C.
.8. Recrystallization of wtSbpA and rSbpA-GG on emulsomes
1 mg  lyophilized S-layer protein was dissolved in 1 mL  5 M GHCl
0 mM Tris/HCl buffer (pH 7.2). The solutions were dialysed against
istilled water at least 24 h at 20 ◦C. For recrystallization of the S-
ayer protein on emulsomes, the S-layer protein solution was  mixed
ith the emulsome suspension and diluted with Milli-Q water to
chieve ﬁnal protein and DPPC concentrations of 300 g mL−1 and
50 g mL−1, respectively. Recrystallization of the S-layer protein
as carried out for 3 h at room temperature in a test tube rotator
REAX2, Heidolph, Germany) with a rotation speed of 32–36 rpm.
xcess non-assembled S-layer protein was removed by centrifu-
ation at 14,100 × g for less than 1 min. The pellet containing the
-layer coated emulsomes was resuspended in Milli-Q water and
tored at 4 ◦C until further analysis.
.9. Afﬁnity assay with human IgG (HIgG) and anti-human IgG
old conjugates (˛-HIgG-Au)
Reagent grade HIgG was dissolved in 10 mM PBS (pH 7.4) with
 ﬁnal antibody concentration of 500 g mL−1. Emulsomes coated
ith rSbpA-GG were mixed with this solution in a 1:2 protein
ass ratio, and the volume was adjusted with 10 mM PBS (pH 7.4)
o achieve a ﬁnal emulsome concentration of 150 g DPPC mL−1
i.e., ﬁnal HIgG concentration = 300 g mL−1). The obtained mix-
ure was incubated for 2–2.5 h at room temperature in the test
ube rotator with a rotation speed of 32–36 rpm. The sample was
hen centrifuged for 2 min. The supernatant was discarded, the pel-
et was resuspended in 10 mM PBS (pH 7.4) and the centrifugation
as repeated. Again the supernatant was discarded and the pellet
as dissolved in 50 L 10 mM PBS (pH 7.4). The obtained product,
orresponding to HIgG-immobilized rSbpA-GG coated emulsomes,
as incubated in ﬁrst 1:10 and then 1:5 diluted -chain speciﬁc
-HIgG-Au (G0786, Sigma–Aldrich, Germany) for 10 and 15 min,
espectively, at 20 ◦C in the Eppendorf thermomixer (Eppendorf,
ustria). Accordingly, 10 L of rSbpA-GG + HIgG coated emulsome,
orresponding to nearly 5 g of DPPC, was mixed with 10 L of
:5 diluted -HIgG-Au conjugate and incubated for 10 min. The
olution was centrifuged 90 s at 14,100 × g, and the colorless super-
atant was discarded. The incubation was repeated this time by: Biointerfaces 128 (2015) 132–139
directly applying 10 L of 1:5 diluted -HIgG-Au conjugate onto the
pellet. The mixture was incubated 15 min  at 20 ◦C in an Eppendorf
thermomixer, after which it was  centrifuged and the supernatant
was removed. The faint red color of the supernatant indicated that
free gold conjugates were present in the broth, implying that satu-
ration should be reached. Pellets were dissolved with Milli-Q water
or 10 mM PBS solution (pH 7.4). The ﬁnal product was analyzed by
TEM after negative staining as described in Ucisik et al. [10].
2.10. TEM
The shape, the integrity of the emulsomes, and the lattice of
recrystallized S-layer proteins were analyzed with a FEI Tecnai G2
20 Transmission Electron Microscope (TEM) at 80 kV equipped with
FEI Eagle 4k camera (FEI Europe, The Netherlands) after a negative
stain preparation.
2.11. Quantiﬁcation of curcumin by absorbance measurements
Curcumin concentration in samples was  estimated as described
previously [19]. Sample absorbance was  measured at 430 nm using
an Inﬁnite F200 plate reader (TECAN, Austria).
2.12. Dynamic light scattering and zeta potential
Emulsomes in 1 mM  KCl solution (pH 6.3) to a ﬁnal DPPC con-
centration of 4 g mL−1 were analyzed with a Zetasizer (Zetasizer
Nano ZS, Malvern Instruments Ltd., UK) to determine the particle
size distribution (dynamic light scattering; DLS) and zeta poten-
tial (Phase Analysis Light Scattering; M3  PALS). The zeta potential
values were calculated from the electrophoretic mobility using the
Smoluchowski model [10]. The conductivity of the buffer varied in
the range of 0.16–0.18 mS  cm−1 at each measurement.
3. Results
3.1. Heterologous expression of the fusion protein rSbpA-GG
The optimum expression of the fusion protein was found to be
at 4 h after induction (Fig. 1, lane 3). SDS-PAGE of samples collected
during the isolation procedure showed that rSbpA-GG had accumu-
lated in the insoluble fraction of the lysed E. coli BL21 (DE3) Star host
cells (data not shown). Following gel-permeation chromatography,
SDS-PAGE analysis showed a single protein band with an appar-
ent molecular mass of 130 kDa (Fig. 1, lane 4) which conﬁrmed
the purity of the protein. Membrane proteins are known to size
anomalously on SDS-PAGE calibrated with conventional standards
[25], explaining the high relative molecular mass value in compari-
son to the formula molecular weight of 116 kDa. The rSbpA-GG was
expressed and puriﬁed with an overall yield of 55 mg protein out
of 2 g wet biomass pellet.
3.2. Self-assembly properties of rSbpA-GG
Puriﬁed rSbpA-GG was recrystallized on poly-l-lysine (PLL) pre-
coated copper grids and on a silicon wafer. As shown by TEM images
of negatively stained preparations, rSbpA-GG reassembled into ﬂat
sheets, which clearly exhibited the square (p4) lattice structure of
wild type (wt) SbpA (see Supplementary data Fig. 1A). The self-
assembly characteristics of the rSbpA-GG were also veriﬁed on a
planar silicon wafer via AFM studies (Supplementary data Fig. 1B).3.3. Detection of IgG binding properties of rSbpA-GG
ELISA plates coated with rSbpA-GG were incubated with peroxi-
dase (POX) labeled HIgG (developed in goat). The color change after
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Fig. 1. SDS/PAGE pattern of protein extract of E. coli BL21 (DE3) Star cells: (1) before
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Table 1
Average values for zeta potential of emulsomes and CurcuEmulsomes before and
after being coated with rSbpA-GG fusion protein.
Zeta potential before
rSbpA-GG coating (mV)a
Zeta potential after
rSbpA-GG coating (mV)
Emulsomeb 32.4 ± 5.9 mV  −19.5 ± 3.7 mV
CurcuEmulsomec 29.8 ± 2.1 mV  −22.7 ± 3.7 mV
a Data were recorded at the day of recrystallization.
b More than 10 separate samples with average conductivity of
0.158 ± 0.011 mS cm−1.
c −1nduction; (2) 2 h after induction; (3) 4 h after induction; and (4) after puriﬁcation.
pplication of POX substrate conﬁrmed the binding. For controls,
arallel studies were performed with (i) recombinant (r) S-layer
rotein rSbpA lacking IgG binding domains, as well as (ii) previously
ngineered rSbpA-ZZ proteins comprising two  protein A domains
used to the SbpA [24]. The goat IgG bound to ELISA plates coated
ith rSbpA-ZZ at a much lower level (Fig. 2), which is in accor-
ance with the weak afﬁnity of protein A for goat IgG as described
n literature [26,27]. Plates coated with rSbpA exhibited as expected
o signiﬁcant binding of IgG. The results obtained clearly demon-
trated that goat IgG was only bound to rSbpA-GG coated plates,
onﬁrming the species independent IgG afﬁnity of protein G, and
lso the fact that protein G molecules genetically fused to the S-
ayer preserve their distinctive IgG binding characteristics.
ig. 2. ELISA results showing binding afﬁnity of HIgG POX (developed in goat)
n  reassembled (from left to right) rSbpA, rSbpA-ZZ and rSbpA-GG monolayers
btained by the ELISA. Developed yellow color was  read at 450 nm on a microplate
eader. The standard deviation (SD) is given as bars within the graph (n = 3).10 separate samples with average conductivity of 0.175 ± 0.003 mS cm . Stan-
dard deviations given by the ±values correspond to the average standard deviation
of  all measurements, where n ≥ 3.
3.4. Emulsomes
Emulsomes were characterized with respect to their intrastruc-
ture and physical characteristics as described in detail by Ucisik
et al. [10]. Following the same methodology, the average diameter
of emulsomes was  found to be 297 ± 28 nm and zeta potential was
32.4 ± 5.9 mV.  The conﬁdence intervals represent the variation of
average values of different formulations.
3.5. CurcuEmulsomes
In the present study, the curcumin concentration in the sus-
pension was either 30 or 110 g mL−1, with the curcumin being
concentrated inside the solid fat core of the emulsomes. Unless
otherwise speciﬁed, all results described in this work refer to
CurcuEmulsome suspensions with 30 g mL−1 curcumin. This cur-
cumin concentration in the suspension corresponds to a 2700-fold
increase over the 11 ng mL−1 maximum solubility of curcumin in
water [28]. The incorporation of curcumin did not inﬂuence either
the size or the zeta potential characteristics of the emulsomes sig-
niﬁcantly. CurcuEmulsomes are spherical in shape with an average
diameter of 291 ± 48 nm and have an average zeta potential of
29.8 ± 2.1 mV.  The conﬁdence intervals represent the variation of
average values of different formulations.
3.6. Recrystallization of rSbpA-GG on emulsomes and
CurcuEmulsomes
Upon recrystallization, rSbpA-GG coated the entire surface of
both emulsomes and CurcuEmulsomes, assembling into the char-
acteristic square lattice symmetry as evidenced by TEM (Fig. 3). It
is important to emphasize that rSbpA-GG (Fig. 3A and B) displays
the same lattice symmetry as wtSbpA (Fig. 3C), i.e., unit-by-unit
distance of 13.1 nm and base angle  = 90◦ [29].
The recrystallization of the S-layer protein altered the zeta
potential of the nanoformulations. Hexadecylamine present in
the phospholipid layer confers a net positive charge (Table 1),
which upon coating with rSbpA-GG became negative: the zeta
potentials were found to be −19.5 ± 3.7 mV  and −22.7 ± 3.7 mV for
coated emulsomes and CurcuEmulsomes, respectively. These val-
ues were comparable to the zeta potential of emulsomes coated
with wtSbpA, which was −18.7 ± 4.0 mV.  The presence of two
protein G domains seems not to cause any signiﬁcant change
in the zeta potential value of the wild type protein, which is in
accordance with a previous study reporting that protein G immo-
bilized polymersomes have a zeta potential close to this value, i.e.,
−17.0 ± 0.2 mV [30]. Evidently, rSbpA-GG has the same capabil-
ity as wtSbpA to recrystallize on the surface of emulsomes, and
the entrapped curcumin has no signiﬁcant inﬂuence on the S-
layer recrystallization process. One may  therefore speculate that
the ability of the fusion protein rSbpA-GG to modify the sur-
face of the emulsomes is independent of any loaded drug in
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wig. 3. TEM images of (A) an emulsome; (B) a CurcuEmulsome completely covered
orrespond to 100 nm.
ow enough concentrations. Increasing the curcumin concentration
as, however, found to affect the S-layer self-assembly; no recrys-
allization of rSbpA-GG was observed at a curcumin concentration
f 110 g mL−1.
.7. Antibody binding characteristics of rSbpA-GG coated
mulsomes
In previous studies, SbpA fusion proteins modiﬁed with some
ther functional moieties were recrystallized on positively charged
iposomes [31], secondary cell wall polymer-coated solid supports
32,33] and microbeads [24]. Most importantly, the conforma-
ional structures as well as the characteristic features of the fused
oieties were preserved. Likewise, immobilized on the surface,
rotein G domains must preserve their conformational 3D struc-
ure in order to present their inherent ability to recognize IgG.
he S-layer rSbpA-GG attaches to the phospholipid surface via
ts N-terminus and is therefore expected to orient the two  C-
erminally fused protein G domains toward the outer face. This
ind of C-terminus exposed orientation would contribute to pre-
ention of possible nonspeciﬁc hydrophobic interactions between
rotein G and the lipid surface, thereby enabling the protein G
omains to maintain their tertiary conformation. The IgG is there-
ore expected to bind to the modiﬁed emulsomes via its antibody
ail (Fc) region, leaving the Fab portion available for antigen bind-
ng. The accuracy of this assertion was investigated as described
elow.
Anti-human IgG gold conjugates (-HIgG-Au) were used to
erify the antibody binding properties of the S-layer coated emul-
omes. First, rSbpA-GG coated emulsomes were incubated with
IgG. The resulting product was then incubated with -HIgG-
u which bound to HIgG (Fig. 4A) and enabled the detection of
inding via TEM (Fig. 4B). The main advantages of this approach
re that it conﬁrms the binding while also indicating the loca-
ions of single binding sites and verifying the C-terminus oriented
ccessibility of protein G molecules on the lattice. The bound Au
onjugates in several regions several regions can be seen to fol-
ow the same square symmetry of the underlying S-layer (Fig. 4C,
rrows).
For a negative control, the same procedure was repeated with
SbpA coated emulsomes lacking the protein G domains. Some
onspeciﬁc binding was observed (Fig. 4D) and attributed to
he afﬁnity of S-layer protein for gold [34]. The relatively low
inding of -HIgG-Au on SbpA coated emulsomes indicated that
he interaction between the S-layer and gold is weak compared to
he strong interaction between HIgG and -HIgG-Au. The speciﬁc
gG recognition of rSbpA-GG coated emulsomes was conﬁrmed
sing an additional approach (Supplementary data Fig. 2), in
hich the interaction between the -HIgG-Au and HIgG-FITC S-layer fusion protein rSbpA-GG; (C) an emulsome coated with wtSbpA. Bar sizes
coated emulsomes was visualized under a confocal laser scanning
microscope (Supplementary data Fig. 3).
4. Discussion
On the positively charged outermost shell of the emulsomes and
CurcuEmulsomes, both wtSbpA and rSbpA-GG reassemble to the
same coherent crystalline lattice with square symmetry (Fig. 3).
The recrystallization of rSbpA-GG on the surface of CurcuEmul-
somes causes a shift in the zeta potential of the nanocarrier from
29.8 ± 2.1 mV  to −22.7 ± 2.1 mV  (Table 1), thereby conﬁrming the
nanocarriers are completely covered with the S-layer of rSbpA-GG.
Clearly, these ﬁndings provided evidence that CurcuEmulsomes can
be coated with rSbpA-GG and that the presence of curcumin inside
the nanocarrier at the concentration used here (i.e., 30 g mL−1)
had no inﬂuence on the S-layer recrystallization characteristics.
It is important to emphasize that this curcumin concentration is
sufﬁciently high to enable its medical use (i.e., IC50: 2–40 g mL−1
[35]).
As recently reported, it is possible to increase the curcumin
content of CurcuEmulsomes up to 110 g mL−1 [19]. At this con-
centration, the curcumin was  found to affect the self-assembly of
the S-layer proteins, preventing the recrystallization of rSbpA-GG.
This may  be due to nonspeciﬁc absorption of curcumin on the sur-
face of the emulsome. As a result, the recrystallization process of
the S-layer protein may  be disturbed. On the other hand, it is also
possible that incorporation of curcumin in very high amounts may
inﬂuence the stiffness or roughness of the outermost phospholipid
bilayer of the nanocarrier, factors which can affect the recrystalliza-
tion [36]. A full understanding and clariﬁcation merits a detailed
further study, which is out of the scope of this work.
The relative IgG afﬁnities of rSbpA-GG, SbpA and SbpA-ZZ were
qualitatively evaluated by monitoring the binding of POX labeled
goat IgG. The results obtained clearly showed that goat IgG binds
strongly only to plates coated with rSbpA-GG; the rSbpA-ZZ with
its protein A domains had a very low afﬁnity for goat IgG, and
rSbpA displayed almost no binding (Fig. 2). These data indicated
that rSbpA-GG possesses strong afﬁnity toward IgG which is con-
ferred by the two fused protein G domains. SbpA lacking the protein
G moieties does not have any afﬁnity for IgG. In addition, our data
veriﬁed once again that – unlike protein G – protein A shows
lower binding to IgGs from several animal species such as goat
[37].
Following the recrystallization of rSbpA-GG on emulsomes,
HIgG binding afﬁnity of tailored emulsomes was  examined by an
indirect approach (Fig. 4A) in which HIgG binding on the S-layer
was demonstrated by the subsequent coupling of -HIgG-Au con-
jugates. This approach provided not only evidence for binding, but
also showed that HIgG binding to the S-layer follows the p4 lattice
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Fig. 4. (A) Schematic drawing illustrating two-step indirect approach verifying the antibody binding to rSbpA-GG coated emulsomes. First, HIgG molecules are recognized
by  the rSbpA-GG coated CurcuEmulsomes and bind to the lattice. The -HIgG-Au conjugates then interact with the bound HIgG. (B) A TEM image of an rSbpA-GG coated
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imulsome upon which HIgG and -HIgG-Au conjugates were bound speciﬁcally. Th
inding follows the p4 symmetry on the S-layer lattice. The bar corresponds to 10 n
onjugates were bound nonspeciﬁcally. The scale bar corresponds to 100 nm.
ymmetry (Fig. 4B). Confocal laser scanning microscopy analysis
ith FITC-labeled HIgG provided further evidence that HIgG specif-
cally binds to the rSbpA-GG lattice on the emulsomes, and hence,
SbpA-GG coated emulsomes are functional in terms of speciﬁc IgG
ecognition (Supplementary data, Fig. 3). Again, lacking the func-
ional protein G domains, SbpA coated CurcuEmulsomes do not
isplay any speciﬁc IgG binding.
TEM analysis revealed that not all presented protein G domains
ithin the lattice were occupied by -HIgG-Au conjugates. This
ay  be attributed to the fact that either (i) -HIgG-Au’s could
ot bind to all free HIgG’s immobilized on the S-layer, or (ii) not
ll binding sites on the S-layer, i.e., protein G domains, were sat-
rated with HIgG. Besides these kinetic parameters, interactions
nd collisions occurring between emulsomes may  also limit anti-
ody binding, as suggested by a previous study [10]. This argument
ould explain why the -HIgG-Au-occupied regions are present
s patches instead of the -HIgG-Au being distributed homoge-
eously on the S-layer lattice (Fig. 4B).
As alternative to our genetic approach, HIgG could be covalently
i.e., chemically) linked to the S-layer lattice as previously reported
38–40]. However, the present approach using site-mutagenesis
eneﬁts from the speciﬁc interactions that make the antibody bind-
ng (Fab) regions to become accessible for antigen binding (Fig. 5).e bar corresponds to 100 nm. (C) Inset image, where the arrows indicate that HIgG
) A TEM image of an rSbpA coated emulsome upon which HIgG and/or -HIgG-Au
This inherent control over orientation of HIgG may further con-
tribute to direct the CurcuEmulsomes toward IgG speciﬁc cells, in
particular inﬂammatory and cancer cells [11], a topic that will be a
focus of our forthcoming studies.
In nanomedicine, particular care has to be taken with the par-
ticles’ surfaces to avoid innate immune system recognition and to
secure sufﬁciently long circulation half-lives for the agents to reach
their targets [41]. As the most common approach, surface-bound
biocompatible polyethylene glycol (PEG) allows the formation of a
hydrated steric barrier that decreases nanocarrier interaction with
blood-borne components. This causes an increased blood circula-
tion time, decreased spleen and liver capture, and improved tumor
uptake [22]. The PEG cushion reduces the adhesion of opsonins
present in the blood serum on nanoparticles [42], and the immuno-
logical response is reduced [43]. The S-layer proteins described
here may  provide an alternate approach for surface modiﬁcation.
The S-layer protein SbpA was  recently shown to form (at basic
pH) smooth, cytophobic patterns that eliminate the adsorption of
human plasma proteins [44], as well as the adhesion of cells (e.g.,
HepG2) [45]. The SbpA coating may  therefore minimize the adhe-
sion of opsonins and enhance the circulation time of the modiﬁed
emulsomes. These anti-fouling characteristics of the SbpA layer are
expected to beneﬁt CurcuEmulsomes in vivo, potentially improving
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. Conclusions
The present study introduces CurcuEmulsomes coated with
SbpA-GG as a nanoparticulate DDS that mimics a viral enve-
ope. The S-layer fusion protein was shown to form a uniform
onomolecular lattice on the surface of the emulsomes and the
urcuEmulsomes, altering the surface characteristics of the lipid-
ased nanocarrier and bestowing IgG binding functionality on the
anocarrier. Entrapped curcumin at a concentration of 30 g mL−1
id not inﬂuence the self-assembly characteristics of the S-layer
rotein. This study indicates that S-layer fusion technology is a
ighly effective approach for immobilization of foreign proteins
uch as protein G domains on emulsomes. The distinct advan-
age of using S-layer proteins is that they can be recrystallized
n an oriented fashion on a variety of supports including spheri-
al surfaces covered by phospholipids [46]. Previous studies have
lso shown that mixtures of native S-layer proteins [47] and S-
ayer fusion proteins incorporating different functional domains
46] assemble into coherent monomolecular layers on different
urfaces including liposomes [48]. Moreover, the predetermined
rientation of the proteins in the S-layer lattice ensures that the
unctional regions of the foreign protein (such as Fab regions) will
e accessible for functions such as antigen binding. The high afﬁn-
ty of HIgG toward rSbpA-GG on the surface of CurcuEmulsomes
nderlines the potential of the proposed system for in vivo drug
elivery. Such multi-faceted and versatile nanocarriers and drug
elivery systems promise a substantial increase in the efﬁcacy of
iagnostic and therapeutic applications in pharmaceutical sciences.
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